In a world-first clinical trial, Tryp Therapeutics is testing whether a psychedelic infusion can curb the compulsions of the most common eating disorder in the US.
Tryptamine Therapeutics (ASX:TYP) delivers promising interim results from its Phase 2a trial, with 75% of IBS patients reporting reduced abdominal pain and anxiety, marking a significant step for TRP-8803’s clinical pathway.
Tryp Therapeutics (ASX:TYP) has secured AUD $6 million in funding to accelerate its flagship IV-infused psilocin treatment, TRP-8803, marking a pivotal step in advancing clinical solutions for treatment-resistant psychiatric conditions.
Tryptamine Therapeutics has reached a pivotal milestone with the successful safety evaluation of its IV-infused psilocin formulation, TRP-8803, setting the stage for broader clinical trials.